International Randomized Study of Interferon Vs STI571 (IRIS) 8-Year Follow up: Sustained Survival and Low Risk for Progression or Events in Patients with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Treated with Imatinib.

Abstract Abstract 1126 Poster Board I-148 Background The IRIS study demonstrated superior safety and efficacy of imatinib (IM) relative to interferon-αa + cytarabine. Based on results from this trial, IM is currently recommended as front-line therapy for CML-CP patients (pts). We report 8-yr follow-up of IRIS, evaluating long-term efficacy and safety of IM. Methods The 553 pts randomized to first-line IM were evaluated for cytogenetic and molecular responses, event-free survival (EFS), progression to accelerated-phase (AP) or blast crisis (BC), overall survival (OS), discontinuations, and frequency of serious adverse events (SAEs). EFS was defined as time until the first occurrence of any of the following:…